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 Osteoarthritis (OA) is a common chronic joint condition, affecting around 27 
million people worldwide with an annual cost of over $100 billion in the United States 
alone.1 It is a degenerative disease classified by the progressive degradation of the 
articular cartilage due to processes such as depletion of proteoglycans, hypertrophic 
differentiation of chondrocytes, surface erosion, and lesion formation in the subchondral 
bone and cartilage.2 Recently, OA has been linked to synovitis in the knee as well, 
showing that OA is a condition that effects the whole joint, not just the cartilage.3 The 
Medial Meniscal Transection (MMT) model is a post-traumatic mechanical model of OA, 
in which the destabilization of the medial meniscus results in characteristic features of 
human OA. Although the MMT model is the industry standard for therapeutic testing, 
localized expression events have not been characterized.4 To evaluate prospective tissue 
engineering and regenerative medicine approaches in OA, a reliable test bed must be 
established with well-characterized events. 
 In a microarray gene expression study, we have shown that, in the synovium and 
the articular cartilage, genes typically associated with OA showed similar altered 
expression in the MMT model. These results were then validated using 
immunohistochemistry tools. Sections of medial and lateral sides of the articular cartilage 
and synovium were stained for chondrogenic and osteogenic proteins, MMPs, and 
inflammatory cytokines, characterizing localized protein expression events in the model 
over time to trace the progression of artificial OA in the model and better establish a 






 OA used to be considered a purely mechanical cartilage-degrading disease. 
Studies mostly concentrated on establishing an animal model that closely mimicked the 
degradation and altered mechanics of the cartilage.5 Studies of this kind relied on the 
assumption that OA is mostly caused by abnormal mechanical stresses and strains on the 
knee. This assumption has not only been proven incorrect, but also made it difficult to 
catch the disease before major damage had been done to the knee. When the lesions were 
big enough to be noticed and OA diagnosed, only a total joint replacement could have 
any effect in alleviating symptoms.6 
The fact that OA affects cartilage and subchondral bone has been well 
established.7 However, not all symptoms of OA can be completely explained by defects 
in the cartilage and bone. OA is often associated with symptoms of inflammation such as 
joint pain, swelling, and stiffness. These symptoms are caused by synovitis in the joint 
based on the infiltration of activated B cells and T lymphocytes and the overexpression of 
pro-inflammatory mediators.3 This helps better understand OA, as it shows that it is a full 
joint condition, affecting the synovium, cartilage, and subchondral bone. 
A study from the Guldberg lab used a micronized, dehydrated amniotic membrane 
(µ-dHACM) known as AmnioFix that was a decellularized extracellular matrix treatment 
method to deliver a large quantity of growth factors to the targeted area.2 This attempted 
to attenuate cartilage degradation in the MMT rat model of OA. Animals were divided 
into three groups: the first received the AmnioFix injection without an MMT surgery, the 
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second received the surgery and the injection, and the third received the surgery but only 
a saline injection. Of the two groups that received the MMT surgery, the ones who had 
also received the injection showed no lesions and significantly reduced partial erosions. 
This shows that AmnioFix does have a protective effect on the lesion formation in the 
MMT model. AmnioFix has a range of immodulary factors that may ameliorate OA 
progression. However, one shortcoming of an extracellular matrix type treatment method 
is that it is difficult to know exactly why it is doing what it is doing. Further studies are 
necessary to figure out exactly which factors of OA and what specific pathways are 
affected by the treatment. 
Our study aims to investigate localized disease-modifying mechanisms involved 
in the disease progression of the MMT model. First, a microarray was used to study gene 
expression in the cartilage of the medial tibial plateau and the medial synovial membrane. 
Then, fluorescent immunohistochemical staining was used to confirm these results by 
studying protein expression throughout the joint space as well. Identified changes in gene 
expression could be used to confirm the similarities between human OA and the 






  Surgeries were done on the left legs of Lewis rats only, allowing the right legs to 
be used as contralateral controls. The animals were divided into groups of 9, depending 
on if they were to receive the MMT or sham surgeries.  In each surgery, a small incision 
was made on the medial side of the left knee. The medial collateral ligament was exposed 
by blunt dissection and transected to visualize the joint space. For the MMT rats, the 
medial meniscus was transected completely at its narrowest point. Sham surgeries were 
used as another control to show that the surgery itself is not causing some of the 
expression changes until the meniscus is transected so for the sham rats, the meniscus 
was not cut. After this, the incisions were closed using staples and casting. After one 
week, an equal number of animals from each group were euthanized. For the other rats, 
the staples were removed. Three weeks after surgery, the remaining rats were euthanized. 
In all cases, after euthanasia, samples from the medial and lateral tibial cartilage and 
synovium were taken from all legs for further study. 
 
Gene Expression Analysis 
 Samples were taken from the medial side of the articular cartilage on the tibial 
plateau as well as the medial synovium. RNA was extracted from the samples and, from 
that, cDNA was isolated. This cDNA was used in a Fluidigm microarray of multiple 
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different genes that have been shown to be affected in human OA. The genes tested are 
listed in Table 2.1. The results of this study were expressed in clustergrams comparing 
the overall gene expression as well as plotting the change in expression in each gene 
individually. 
Symptom of OA Genes Studied 
ECM degradation MMP3, MMP9, MMP13, Timp1, ADAMTS4, ADAMTS5 
Chondrocyte hypertrophy BMP2, Osteocalcin, Osteoprotegerin, Osteopontin, Frizzle-related protein, Grem1, Sox9 
Cell apoptosis Casp8, Tgm2 
Inflammation TNFα, TGFβ-1, IL1-ra, IL1b, IL6, IL8, IL10, IL17, CCL2, CCL3 
 
Protein Expression Analysis 
 Full joints were collected from the animals following euthanasia. These were then 
decalcified using Immunocal, dehydrated, and embedded in paraffin. The entire sample 
was then sectioned manually by cutting 5 µm sections using the microtome. These 
sections were then used for immunohistochemical staining. 
Sections from the edge and center of the medial condyle were stained using 
immunohistochemistry (IHC). Sections were first deparafinized and rehydrated using 
heat, xylene, pure ethanol, and 95% ethanol followed by a wash in tap water. The 
sections then went through antigen retrieval, where they were suspended in a sodium 
citrate buffer in a 60 °C hot water bath overnight. Following this, sides were treated with 
Triton X before being encircled by a hydrophobic barrier drawn on using a PAP pen.  
At this point, the samples were ready to be treated with the primary antibodies 
that were left on the slides overnight in a humidity chamber at 20 °C. The next day, 
Table 2.1 Genes studied in the microarray divided by the symptoms of OA that they are associated with 
in human OA. 
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sections were treated with a normal anti-goat serum followed by a fluorescent secondary 
antibody. After an hour, DAPI was added to the sections and they were sealed with a 






 The microarray showed differences in a variety of gene expression in the medial 
cartilage. The clustergram (Figure 3.1) showed that the MMT surgeries clustered on one 
side of the chart and the sham and control surgeries on the other side, implying that the 
sham and control groups were more like each other and the MMT was different. 
 
 More specifically, Figure 3.2 shows the relative expression of five of the genes 
studied. Chondrogentic hypertrophic genes osteopontin and collagen 1 showed similar 
expression in the sham and control groups with increased expression in the MMT group. 
The same was true for ECM protein fibronectin and matrix degradation protein MMP13. 
For collagen 10, the sham and control groups showed similar expression and decreased 
expression in the MMT group. 
The IHC stains of the cartilage, shown in Figure 3.3, also showed the differences 
between the MMT group and the control groups. Stains for collagen 1, collagen 2, 
Figure 3.1 Clustergram of the gene expression of the medial cartilage. 
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collagen 10, osteopontin, MMP3, and MMP13 could be seen prevalently in the images 




Figure 3.3 Immunohistochemical stains of the cartilage with the top row coming from the week 3 sham 
group, and the bottom from the week 3 MMT group. Each column is a different stain: Collagen 1, Collagen 
2, Collagen 10, and MMP13 from left to right. 
Figure 3.2 Specific expression in the medial cartilage A. Osteopontin expression in Control, Sham, and 
MMT groups. B. Collagen 1 expression in Control, Sham, and MMT group. C. Collagen 10 expression in 
Control, Sham, and MMT group. D. Fibronectin expression in Control, Sham, and MMT group. E. MMP13 
expression in Control, Sham, and MMT group. 




In the medial synovial membrane, the clustergram (Figure 3.4) showed that the 
MMT group was clustered with the week 1 sham samples while the week 3 sham samples 
and control group were clustered on the other side. 
  
Specifically, Figure 3.5 shows the relative gene expression of five genes studied 
in analyzing the synovial membrane. For MMP3, the sham and control groups showed 
Figure 3.4 Clustergram of the gene expression in the medial synovial membrane. 
 
Figure 3.5 Specific expression in the medial synovium A. MMP3 expression in Control, Sham, and MMT 
groups. B. MMP13 expression in Control, Sham, and MMT group. C. Collagen 1a1 expression in Control, 
Sham, and MMT group. D. Collagen 1a2 expression in Control, Sham, and MMT group. E. Osteopontin 
expression in Control, Sham, and MMT group. 
A B 
C E D 
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similar expression while it was upregulated in the MMT groups. For MMP13 and 
Osteopontin, the control and the week 3 sham group showed similar expression while the 
week 1 sham group and MMT groups showed overexpression. For collagen 1a1 and 
collagen 1a2 the sham and MMT groups were significantly upregulated over the control 
groups. 
The IHC Stains of full joint samples backed up the findings in the gene expression 
study. As shown in Figure 3.6, there were differences in the prevalence of collagen 1, 




Figure 3.6 Immunohistochemical stains of the cartilage with the top row coming from the week 3 sham 
group, and the bottom from the week 3 MMT group. Each column is a different stain: Collagen 1 on the 





OA causes breakdown of the extracellular matrix, chondrocyte hypertrophy, 
cellular apoptosis, and inflammation of the synovial membrane, all of which are caused 
by changes in gene and protein expression within the cartilage and, to a certain extent, in 
the rest of the joint. In humans, the genes associated with these factors have been well 
classified. We hypothesized that the MMT model simulates those same changes to an 
extent and is therefore a valid model of preclinical OA. 
 The results of the microarray showed similar upregulation in approximately 70 
percent of the genes studied, implying that most of the same inflammatory, degradation, 
hypertrophy, and apoptosis pathways that are part of human OA are also part of the 
mechanisms of the MMT model. The effect on gene expression was related to pathways 
in chondrocyte hypertrophic, extracellular matrix (ECM) composition and degradation, 
and cartilage catabolism. 
 The protein expression results confirmed the results of gene expression study. 
Specifically, the Collagen 2 stain shows the morphological effects of the model on the 
cartilage, including fibrillations on the cartilage and a lesion beginning to form, as 
compared to the sham which the cartilage remained smooth. The changes expressed in 
the MMT model mirror those typically seen in OA. For the other stains, all showed 
greater expression of the proteins in the MMT model than the sham, implying changes in 
the protein expression and backing the findings of the microarray. 
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 Altogether, the gene and protein analysis of specific locations in the joint space 
show that the MMT model is a good representation of OA. The gene expression analysis 
showed that there were similar genetic changes in the model to those seen in various 
other studies of human OA. The protein expression study confirmed these results as well 
as the local morphological changes of the model. With more extensive studies to fully 
characterize the gene and protein expression profiles of the MMT model, the model could 
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